Skip to content
Open access

Inhibition of Calpain-1 ameliorates doxorubicin-induced cardiotoxicity by suppression of p53-mediated ferroptosis.

Aug 2026 · Toxicology and Applied Pharmacology · pp. 118001 · 0 citations · 53 references
Medicine

TL;DR

It is suggested that Calpain-1 exacerbates DIC by stabilizing p53 to initiate p53-dependent cardiomyocyte ferroptosis, offering a novel therapeutic target and theoretical basis for DIC intervention.

Abstract

Doxorubicin (Dox), a widely applied anthracycline antitumor agent, exhibits severe dose-dependent cardiotoxicity that greatly restricts its clinical utilization, yet the molecular mechanism linking Calpain-1 to cardiomyocyte ferroptosis in doxorubicin-induced cardiotoxicity (DIC) remains poorly clarified. This study aimed to explore how Calpain-1 regulates cardiomyocyte ferroptosis in DIC. Differentially expressed proteins from Dox-treated H9c2 cells were screened by proteomics, stable Calpain-1 knockdown cell lines were generated to detect cell viability and ferroptosis indicators through CCK-8, FerroOrange staining, biochemical kits and western blotting, and PPI network, co-IP and cycloheximide chase assays were performed to confirm Calpain-1-p53 binding and p53 protein stability regulation, with p53 rescue tests further verifying their functional relationship. In vivo, Calpain-1 expression was detected in Dox-exposed mouse hearts, and AAV9-driven myocardial Calpain-1 knockdown was established in DIC mice, where myocardial injury and ferroptosis were evaluated by HE staining, serum CK-MB/LDH and protein detection. Calpain-1 was significantly upregulated in Dox-stimulated cardiomyocytes and cardiac tissue. Calpain-1 silencing alleviated Dox-induced ferroptosis in vitro, with decreased Fe2+, MDA, LPO and ACSL4, elevated GSH and SLC7A11; co-IP verified direct Calpain-1-p53 interaction, and cycloheximide assays proved Calpain-1 inhibits p53 degradation to accumulate p53 protein, whereas p53 overexpression completely abolished the protective effect of Calpain-1 knockdown. Consistent with cellular results, cardiac-specific Calpain-1 knockdown mitigated myocardial damage and suppressed ferroptosis in DIC mice. These findings suggest that Calpain-1 exacerbates DIC by stabilizing p53 to initiate p53-dependent cardiomyocyte ferroptosis, offering a novel therapeutic target and theoretical basis for DIC intervention.

Read PDF

Similar papers

Aug 2026

Isoginkgetin ameliorates doxorubicin-induced cardiotoxicity by inhibiting ferroptosis via the SIRT1/NRF2 pathway.

BACKGROUND Doxorubicin-induced cardiotoxicity (DIC) poses a substantial threat to the prognosis and survival of cancer patients. Ferroptosis, mediated in part by suppression of the SIRT1/NRF2 pathway, has been identified as a critical mechanism underlying DIC. Isoginkgetin (IGK), a naturally occurring biflavonoid with...

H. Mo, Han Su, Zhenyu Zhuang et al. · 0 citations
Open access Sep 2026

Neohesperidin Alleviates Ferroptosis in Doxorubicin-Induced Cardiotoxicity via Mettl3-m6A-Nrf2 Signaling.

Doxorubicin (DOX) has antitumor efficacy, but its clinical application is restricted by multiple side effects, especially cardiotoxicity. Neohesperidin, a flavonoid in citrus fruits, has various health benefits. The aim of this study was to explore the cardioprotective effects and mechanisms of neohesperidin against DO...

Rui-Jia Wen, Xin Dong, Hao-Wen Zhuang et al. · 0 citations
Sep 2026

Infection-associated lipopolysaccharide aggravates doxorubicin-induced cardiotoxicity via modulation of the FOXO1-GPX4 ferroptosis pathway.

Findings indicate that DOX and LPS synergistically promote myocardial injury by activating the FOXO1/GPX4-mediated ferroptosis pathway, providing mechanistic insight into infection-associated cardiotoxicity during DOX chemotherapy.

Tao Zhang, Chu-Chu Wang, Zi-Han Nan et al. · 0 citations
Sep 2026

Acteoside ameliorates doxorubicin-induced cardiotoxicity by suppressing ferroptosis through activation of the KEAP1/NRF2 pathway.

Doxorubicin (DOX)-induced cardiotoxicity (DIC) is a major limitation to the clinical use of DOX, highlighting the need for effective cardioprotective strategies. Although acteoside (ACT), a natural compound with antioxidant properties, has shown potential cardioprotective effects, its role in DIC, particularly in the r...

Meng Wang, Che Wang, Zhi-Hao Liu et al. · 0 citations
Aug 2026

Forsythiaside B alleviates DOX-induced myocardial injury by enhancing the interaction between HSP90AA1 and CYP1A1 to inhibit ferroptosis.

BACKGROUND Doxorubicin (DOX) is a potent anti-tumor drug that is commonly associated with cardiotoxic reactions (DIC) during its use. Ferroptosis in cardiomyocytes is one of the key pathogenic mechanisms of this toxic reaction. Forsythiaside B (FTB) has been proven to have cardioprotective effects, but its role and pot...

Sailing Hu, Ling-Chun Lv, Zhou-Qing Huang · 0 citations
Sep 2026

CTRP4 overexpression mitigates doxorubicin-induced cardiotoxicity by suppressing oxidative stress and ferroptosis through activation of the Sirt1-Nrf2 signaling axis.

Oxidative stress and ferroptosis are major drivers of doxorubicin (DOX)-induced cardiotoxicity. C1q/TNF-related protein 4 (CTRP4) is an endogenous cardioprotective factor that modulates both processes; however, its role and underlying mechanisms in DOX-induced myocardial injury remain unclear. We hypothesized that CTRP...

Jian Wang, Jie Zhang, Nan Wu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.